Cardium is focused on the acquisition and strategic development of new and innovative
biomedical product opportunities and businesses that have the potential to address
significant unmet medical needs and definable pathways to partnering, commercialization
and other economic monetizations. Cardium's investment portfolio
includes the Tissue Repair Company and Cardium Biologics, medical technology
companies primarily focused on the development of innovative therapeutic products
for wound healing, bone repair, and cardiovascular indications.
